Log in
NASDAQ:CSII

Cardiovascular Systems Competitors

$34.90
+0.41 (+1.19 %)
(As of 11/23/2020 12:00 AM ET)
Add
Compare
Today's Range
$34.34
Now: $34.90
$34.97
50-Day Range
$34.49
MA: $36.76
$39.08
52-Week Range
$26.00
Now: $34.90
$55.22
Volume333,159 shs
Average Volume334,002 shs
Market Capitalization$1.40 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.3

Competitors

Cardiovascular Systems (NASDAQ:CSII) Vs. ABT, MDT, SYK, ISRG, BDX, and EW

Should you be buying CSII stock or one of its competitors? Companies in the sub-industry of "health care equipment" are considered alternatives and competitors to Cardiovascular Systems, including Abbott Laboratories (ABT), Medtronic (MDT), Stryker (SYK), Intuitive Surgical (ISRG), Becton, Dickinson and (BDX), and Edwards Lifesciences (EW).

Cardiovascular Systems (NASDAQ:CSII) and Abbott Laboratories (NYSE:ABT) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, risk, institutional ownership, analyst recommendations, earnings, profitability and dividends.

Institutional and Insider Ownership

85.5% of Cardiovascular Systems shares are owned by institutional investors. Comparatively, 63.9% of Abbott Laboratories shares are owned by institutional investors. 3.0% of Cardiovascular Systems shares are owned by company insiders. Comparatively, 1.7% of Abbott Laboratories shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Cardiovascular Systems and Abbott Laboratories, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cardiovascular Systems00703.00
Abbott Laboratories141302.67

Cardiovascular Systems presently has a consensus price target of $45.5714, suggesting a potential upside of 30.58%. Abbott Laboratories has a consensus price target of $115.3750, suggesting a potential upside of 5.59%. Given Cardiovascular Systems' stronger consensus rating and higher probable upside, analysts plainly believe Cardiovascular Systems is more favorable than Abbott Laboratories.

Earnings & Valuation

This table compares Cardiovascular Systems and Abbott Laboratories' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cardiovascular Systems$236.54 million5.92$-27,240,000.00($0.79)-44.18
Abbott Laboratories$31.90 billion6.07$3.69 billion$3.2433.73

Abbott Laboratories has higher revenue and earnings than Cardiovascular Systems. Cardiovascular Systems is trading at a lower price-to-earnings ratio than Abbott Laboratories, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Cardiovascular Systems has a beta of 1.3, indicating that its stock price is 30% more volatile than the S&P 500. Comparatively, Abbott Laboratories has a beta of 0.9, indicating that its stock price is 10% less volatile than the S&P 500.

Profitability

This table compares Cardiovascular Systems and Abbott Laboratories' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cardiovascular Systems-10.12%-11.43%-8.36%
Abbott Laboratories10.50%18.19%8.29%

Summary

Abbott Laboratories beats Cardiovascular Systems on 9 of the 14 factors compared between the two stocks.

Cardiovascular Systems (NASDAQ:CSII) and Medtronic (NYSE:MDT) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, risk, institutional ownership, analyst recommendations, earnings, profitability and dividends.

Institutional and Insider Ownership

85.5% of Cardiovascular Systems shares are owned by institutional investors. Comparatively, 79.9% of Medtronic shares are owned by institutional investors. 3.0% of Cardiovascular Systems shares are owned by company insiders. Comparatively, 0.5% of Medtronic shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Cardiovascular Systems and Medtronic, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cardiovascular Systems00703.00
Medtronic132012.84

Cardiovascular Systems presently has a consensus price target of $45.5714, suggesting a potential upside of 30.58%. Medtronic has a consensus price target of $118.1538, suggesting a potential upside of 6.47%. Given Cardiovascular Systems' stronger consensus rating and higher probable upside, analysts plainly believe Cardiovascular Systems is more favorable than Medtronic.

Earnings & Valuation

This table compares Cardiovascular Systems and Medtronic's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cardiovascular Systems$236.54 million5.92$-27,240,000.00($0.79)-44.18
Medtronic$28.91 billion5.16$4.79 billion$4.5924.18

Medtronic has higher revenue and earnings than Cardiovascular Systems. Cardiovascular Systems is trading at a lower price-to-earnings ratio than Medtronic, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Cardiovascular Systems has a beta of 1.3, indicating that its stock price is 30% more volatile than the S&P 500. Comparatively, Medtronic has a beta of 0.64, indicating that its stock price is 36% less volatile than the S&P 500.

Profitability

This table compares Cardiovascular Systems and Medtronic's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cardiovascular Systems-10.12%-11.43%-8.36%
Medtronic15.80%10.47%5.80%

Summary

Medtronic beats Cardiovascular Systems on 9 of the 15 factors compared between the two stocks.

Cardiovascular Systems (NASDAQ:CSII) and Stryker (NYSE:SYK) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, risk, institutional ownership, analyst recommendations, earnings, profitability and dividends.

Institutional and Insider Ownership

85.5% of Cardiovascular Systems shares are owned by institutional investors. Comparatively, 71.0% of Stryker shares are owned by institutional investors. 3.0% of Cardiovascular Systems shares are owned by company insiders. Comparatively, 6.8% of Stryker shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Cardiovascular Systems and Stryker, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cardiovascular Systems00703.00
Stryker291512.56

Cardiovascular Systems presently has a consensus price target of $45.5714, suggesting a potential upside of 30.58%. Stryker has a consensus price target of $221.44, suggesting a potential downside of 4.97%. Given Cardiovascular Systems' stronger consensus rating and higher probable upside, analysts plainly believe Cardiovascular Systems is more favorable than Stryker.

Earnings & Valuation

This table compares Cardiovascular Systems and Stryker's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cardiovascular Systems$236.54 million5.92$-27,240,000.00($0.79)-44.18
Stryker$14.88 billion5.88$2.08 billion$8.2628.21

Stryker has higher revenue and earnings than Cardiovascular Systems. Cardiovascular Systems is trading at a lower price-to-earnings ratio than Stryker, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Cardiovascular Systems has a beta of 1.3, indicating that its stock price is 30% more volatile than the S&P 500. Comparatively, Stryker has a beta of 0.78, indicating that its stock price is 22% less volatile than the S&P 500.

Profitability

This table compares Cardiovascular Systems and Stryker's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cardiovascular Systems-10.12%-11.43%-8.36%
Stryker11.38%20.53%8.89%

Summary

Stryker beats Cardiovascular Systems on 10 of the 15 factors compared between the two stocks.

Cardiovascular Systems (NASDAQ:CSII) and Intuitive Surgical (NASDAQ:ISRG) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, risk, institutional ownership, analyst recommendations, earnings, profitability and dividends.

Institutional and Insider Ownership

85.5% of Cardiovascular Systems shares are owned by institutional investors. Comparatively, 86.9% of Intuitive Surgical shares are owned by institutional investors. 3.0% of Cardiovascular Systems shares are owned by company insiders. Comparatively, 1.6% of Intuitive Surgical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Cardiovascular Systems and Intuitive Surgical, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cardiovascular Systems00703.00
Intuitive Surgical371202.41

Cardiovascular Systems presently has a consensus price target of $45.5714, suggesting a potential upside of 30.58%. Intuitive Surgical has a consensus price target of $718.2778, suggesting a potential downside of 0.11%. Given Cardiovascular Systems' stronger consensus rating and higher probable upside, analysts plainly believe Cardiovascular Systems is more favorable than Intuitive Surgical.

Earnings & Valuation

This table compares Cardiovascular Systems and Intuitive Surgical's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cardiovascular Systems$236.54 million5.92$-27,240,000.00($0.79)-44.18
Intuitive Surgical$4.48 billion18.87$1.38 billion$9.9572.27

Intuitive Surgical has higher revenue and earnings than Cardiovascular Systems. Cardiovascular Systems is trading at a lower price-to-earnings ratio than Intuitive Surgical, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Cardiovascular Systems has a beta of 1.3, indicating that its stock price is 30% more volatile than the S&P 500. Comparatively, Intuitive Surgical has a beta of 0.97, indicating that its stock price is 3% less volatile than the S&P 500.

Profitability

This table compares Cardiovascular Systems and Intuitive Surgical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cardiovascular Systems-10.12%-11.43%-8.36%
Intuitive Surgical24.45%12.08%10.44%

Summary

Intuitive Surgical beats Cardiovascular Systems on 10 of the 14 factors compared between the two stocks.

Cardiovascular Systems (NASDAQ:CSII) and Becton, Dickinson and (NYSE:BDX) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, risk, institutional ownership, analyst recommendations, earnings, profitability and dividends.

Institutional and Insider Ownership

85.5% of Cardiovascular Systems shares are owned by institutional investors. Comparatively, 74.4% of Becton, Dickinson and shares are owned by institutional investors. 3.0% of Cardiovascular Systems shares are owned by company insiders. Comparatively, 0.1% of Becton, Dickinson and shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Cardiovascular Systems and Becton, Dickinson and's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cardiovascular Systems-10.12%-11.43%-8.36%
Becton, Dickinson and5.11%13.30%5.60%

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Cardiovascular Systems and Becton, Dickinson and, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cardiovascular Systems00703.00
Becton, Dickinson and07712.60

Cardiovascular Systems presently has a consensus price target of $45.5714, suggesting a potential upside of 30.58%. Becton, Dickinson and has a consensus price target of $280.2857, suggesting a potential upside of 22.67%. Given Cardiovascular Systems' stronger consensus rating and higher probable upside, analysts plainly believe Cardiovascular Systems is more favorable than Becton, Dickinson and.

Earnings & Valuation

This table compares Cardiovascular Systems and Becton, Dickinson and's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cardiovascular Systems$236.54 million5.92$-27,240,000.00($0.79)-44.18
Becton, Dickinson and$17.12 billion3.87$874 million$10.2022.40

Becton, Dickinson and has higher revenue and earnings than Cardiovascular Systems. Cardiovascular Systems is trading at a lower price-to-earnings ratio than Becton, Dickinson and, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Cardiovascular Systems has a beta of 1.3, indicating that its stock price is 30% more volatile than the S&P 500. Comparatively, Becton, Dickinson and has a beta of 0.83, indicating that its stock price is 17% less volatile than the S&P 500.

Summary

Becton, Dickinson and beats Cardiovascular Systems on 8 of the 14 factors compared between the two stocks.

Cardiovascular Systems (NASDAQ:CSII) and Edwards Lifesciences (NYSE:EW) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, institutional ownership, profitability, valuation and earnings.

Insider and Institutional Ownership

85.5% of Cardiovascular Systems shares are owned by institutional investors. Comparatively, 79.7% of Edwards Lifesciences shares are owned by institutional investors. 3.0% of Cardiovascular Systems shares are owned by insiders. Comparatively, 1.5% of Edwards Lifesciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares Cardiovascular Systems and Edwards Lifesciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cardiovascular Systems-10.12%-11.43%-8.36%
Edwards Lifesciences18.18%29.00%18.10%

Analyst Recommendations

This is a breakdown of current recommendations for Cardiovascular Systems and Edwards Lifesciences, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cardiovascular Systems00703.00
Edwards Lifesciences251302.55

Cardiovascular Systems currently has a consensus target price of $45.5714, indicating a potential upside of 30.58%. Edwards Lifesciences has a consensus target price of $87.7222, indicating a potential upside of 3.57%. Given Cardiovascular Systems' stronger consensus rating and higher possible upside, analysts plainly believe Cardiovascular Systems is more favorable than Edwards Lifesciences.

Earnings & Valuation

This table compares Cardiovascular Systems and Edwards Lifesciences' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cardiovascular Systems$236.54 million5.92$-27,240,000.00($0.79)-44.18
Edwards Lifesciences$4.35 billion12.14$1.05 billion$1.8645.54

Edwards Lifesciences has higher revenue and earnings than Cardiovascular Systems. Cardiovascular Systems is trading at a lower price-to-earnings ratio than Edwards Lifesciences, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Cardiovascular Systems has a beta of 1.3, meaning that its share price is 30% more volatile than the S&P 500. Comparatively, Edwards Lifesciences has a beta of 0.92, meaning that its share price is 8% less volatile than the S&P 500.

Summary

Edwards Lifesciences beats Cardiovascular Systems on 9 of the 14 factors compared between the two stocks.


Cardiovascular Systems Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Abbott Laboratories logo
ABT
Abbott Laboratories
2.2$109.27+1.5%$193.67 billion$31.90 billion57.82
Medtronic logo
MDT
Medtronic
2.7$110.97+0.7%$149.17 billion$28.91 billion33.94
Stryker logo
SYK
Stryker
2.0$233.01+0.1%$87.56 billion$14.88 billion55.35
Intuitive Surgical logo
ISRG
Intuitive Surgical
1.7$719.05+1.6%$84.53 billion$4.48 billion81.90
Becton, Dickinson and logo
BDX
Becton, Dickinson and
2.0$228.48+1.5%$66.23 billion$17.12 billion83.69Increase in Short Interest
Edwards Lifesciences logo
EW
Edwards Lifesciences
1.8$84.70+0.2%$52.79 billion$4.35 billion67.76
Boston Scientific logo
BSX
Boston Scientific
2.4$33.33+1.1%$47.73 billion$10.74 billion12.77
IDEXX Laboratories logo
IDXX
IDEXX Laboratories
1.5$459.79+1.0%$39.22 billion$2.41 billion80.10
Baxter International logo
BAX
Baxter International
2.3$75.77+1.6%$38.70 billion$11.36 billion43.05Increase in Short Interest
DexCom logo
DXCM
DexCom
2.1$321.09+1.6%$30.83 billion$1.48 billion132.68
ResMed logo
RMD
ResMed
1.7$209.57+0.7%$30.37 billion$2.96 billion49.08
Insulet logo
PODD
Insulet
1.3$265.89+0.2%$17.53 billion$738.20 million949.64
Hologic logo
HOLX
Hologic
1.9$68.07+1.4%$17.49 billion$3.37 billion16.21Analyst Downgrade
Teleflex logo
TFX
Teleflex
1.8$373.14+0.7%$17.38 billion$2.60 billion36.73
STERIS logo
STE
STERIS
1.9$189.09+3.5%$16.13 billion$3.03 billion39.31
Varian Medical Systems logo
VAR
Varian Medical Systems
1.4$173.50+0.0%$15.78 billion$3.23 billion56.51
Masimo logo
MASI
Masimo
1.6$245.50+1.0%$13.52 billion$937.84 million63.77
Abiomed logo
ABMD
Abiomed
1.5$266.43+0.7%$12.04 billion$840.88 million58.56
Hill-Rom logo
HRC
Hill-Rom
1.9$97.55+0.1%$6.52 billion$2.91 billion31.47Unusual Options Activity
Globus Medical logo
GMED
Globus Medical
1.5$58.47+1.1%$5.77 billion$785.37 million63.55
Integra LifeSciences logo
IART
Integra LifeSciences
1.4$54.78+0.5%$4.62 billion$1.52 billion81.76
Wright Medical Group logo
WMGI
Wright Medical Group
1.1$29.98+0.0%$3.90 billion$920.90 million-28.28
CONMED logo
CNMD
CONMED
1.5$103.32+2.0%$2.96 billion$955.10 million108.76Dividend Announcement
Insider Selling
NuVasive logo
NUVA
NuVasive
1.8$47.18+2.3%$2.42 billion$1.17 billion-214.45
Integer logo
ITGR
Integer
2.2$71.37+2.1%$2.35 billion$1.26 billion32.44
AtriCure logo
ATRC
AtriCure
1.5$43.24+1.8%$1.95 billion$230.81 million-37.60
Alphatec logo
ATEC
Alphatec
1.2$10.55+2.4%$827.38 million$113.43 million-9.59
CryoLife logo
CRY
CryoLife
2.1$20.87+4.0%$810.95 million$276.22 million-54.92
Orthofix Medical logo
OFIX
Orthofix Medical
1.4$37.14+2.7%$718.07 million$459.95 million30.95
Surmodics logo
SRDX
Surmodics
1.5$38.12+2.4%$518.66 million$100.08 million68.07
AngioDynamics logo
ANGO
AngioDynamics
1.5$12.52+0.6%$475.17 million$264.16 million-2.83
Accuray logo
ARAY
Accuray
2.0$4.40+11.1%$401.61 million$382.93 million31.43High Trading Volume
Unusual Options Activity
Invacare logo
IVC
Invacare
1.4$8.98+1.1%$309.07 million$927.96 million-7.30
Rockwell Medical logo
RMTI
Rockwell Medical
1.3$0.94+1.1%$88.32 million$61.30 million-2.10
This page was last updated on 11/24/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.